Nifuratel

Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases^{[1][2][3][4][5][6][7][8]}. In Vitro:Nifuratel kills all Salmonella in RAW264.7 cells at 25 µM. Nifuratel kills all Salmonella in mouse J774.1 cells, avian HD11 cells, and human Hela cells at 50 µM, 100 µM, and 100 µM, respectively^[4].
Nifuratel (0-100 µM; 15 h) completely inhibits the growth of SE C50041 strain in broth at a concentration of 100 µM^[4].
Nifuratel (10-300 µM; 24 h) dose-dependently reduces colony formation in SGC7901 and BGC-823 cell lines with IC₅₀ values ​​of 169.7 µM and 133.7 µM^[5].
Nifuratel (75-300 µM; 24 h) blocks IL-6-induced activation of the STAT3 signaling pathway in SGC-7901 and BGC-823 cell lines^[5].
Nifuratel inhibits antigen-induced degranulation in both RBL-2H3 cells and BMMCs in a concentration-dependent manner, with IC₅₀ values ​​of 0.34 µM and 0.9 µM^[6].
Nifuratel (0-3 µM; 30 min) dose-dependently inhibits the secretion of histamine from antigen-stimulated mast cells and the release of inflammatory factors TNF-α and IL-4 in antigen-stimulated RBL-2H3 cells, with IC₅₀ values ​​of approximately 0.48 and 0.75 µM^[6].
In Vivo:Beauvericin (10-100 mg/kg; p.o.; oral administration on the day after IgE injection) inhibits IgE-mediated passive cutaneous anaphylaxis in Balb/c mice with an ED₅₀ value of 22 mg/kg^[6].